[{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medical \/ Cancer Focus Fund"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is currently being evaluated for the treatment of solid tumors.

                          Product Name : COM503

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : COM503

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Gilead Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Compugen will exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503, a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding prote...

                          Product Name : COM503

                          Product Type : Antibody

                          Upfront Cash : $60.0 million

                          December 19, 2023

                          Lead Product(s) : COM503

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Gilead Sciences

                          Deal Size : $848.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of solid tumors and Pancreatic Cancer and has received Fast Track designation and Orphan Drug Designation for adult patients with low-gr...

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 07, 2023

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...

                          Product Name : Alpha Dart

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 03, 2023

                          Lead Product(s) : Radium-224

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Alpha DaRT (Radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral insertion of radium-224 impregnated seeds.

                          Product Name : Alpha Dart

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2022

                          Lead Product(s) : Radium-224

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination w...

                          Product Name : Allocetra

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 06, 2022

                          Lead Product(s) : Allocetra,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.

                          Product Name : BND-22

                          Product Type : Antibody

                          Upfront Cash : $125.0 million

                          December 01, 2021

                          Lead Product(s) : BND-22

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Sanofi

                          Deal Size : $1,125.0 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies...

                          Product Name : GDA-201

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          October 26, 2021

                          Lead Product(s) : Nam-Expanded Allogeneic NK Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : DSP107 uniquely delivers a multilayered attack by binding cancer cells and T-cells to produce a targeted synergistic effect, combining immune checkpoint inhibition with selective T-cell activation.

                          Product Name : DSP107

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          May 26, 2021

                          Lead Product(s) : DSP107,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Cancer Focus Fund

                          Deal Size : $5.0 million

                          Deal Type : Funding

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.

                          Product Name : ABR-217620

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          April 19, 2021

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank